We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Par Pharmaceutical has announced results of a Phase II proof-of-concept clinical
trial with concentrated megestrol acetate oral suspension. In the trial, patients
taking concentrated megestrol acetate gained more weight, on average, than those
taking the older megestrol acetate oral suspension.
Valeant Pharmaceuticals announced that it intends to initiate enrollment for
a Phase III trial for retigabine, which is being developed as an adjunctive
treatment for partial-onset seizures in patients with epilepsy.
The FDA has granted tentative approval to Teva Pharmaceutical's abbreviated new drug application for fexofenadine HCl tablets in 30-, 60- and 180-mg dosage strengths.
Aeris Therapeuticsa has reported that the FDA has granted fast-track designation for the company's program to develop its Bronchoscopic Lung Volume Reduction (BLVR) system as a non-surgical treatment alternative for selected patients with advanced heterogeneous emphysema.
A team of scientists has discovered three molecules, from a search of 58,000 compounds, that appear to inhibit a key perpetrator of Alzheimer's disease.
Spectrum Pharmaceuticals announced the launch of a Phase I/II trial that will explore the safe and efficacious dose range of ozarelix (formerly SPI-153) as a treatment for patients with hormone-dependent prostate cancer.
Exelixis has initiated a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic profile of XL820, a novel, orally administered, small molecule anticancer compound.
Synthetic Blood International announced that the University of South Florida's Tampa General Hospital is the fifth clinical site to receive investigational review board approval to enroll patients in a 60-patient Phase II Oxycyte trial.